Silybum marianum: An Overview of its Phytochemistry and Pharmacological Activities with Emphasis on Potential Anticancer Properties


Citar

Texto integral

Resumo

Silybum marianum (SM) belongs to the family Asteraceae, which holds therapeutic significance in medicinal chemistry. Phytochemistry analysis revealed an abundance of active constituents, particularly silymarin, composed of polyphenols and flavonolignans. Silymarin is majorly found in leaves, seeds, and fruits and is comprised of seven flavonolignans. Silymarin derivatives, specifically silybin, were reported for their medicinal properties. This review summarizes the studies conducted to evaluate SM's pharmacological properties and proposed mechanisms. SM exhibited anticancer properties due to being capable of modifying the induction of apoptosis, inhibiting the STAT3 pathway, decreasing the transcription of various growth factors, impeding the growth of 4T1 cells and inducing cell cycle arrest in various types of cancers, i.e., skin cancer, liver cancer, breast cancer, ovarian cancer etc. Silymarin and its derivatives protect the liver and ameliorate various immune-mediated and autoimmune hepatic diseases. Moreover, antimicrobial, antidiabetic, cardioprotective, nephroprotective, and neuroprotective activities were also reported. Based on testified in vitro and in vivo studies, SM can serve as an alternative to cure various pathological ailments.

Sobre autores

Aisha Nawaz

Department of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab

Email: info@benthamscience.net

Sumera Zaib

Department of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab

Autor responsável pela correspondência
Email: info@benthamscience.net

Imtiaz Khan

Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester

Autor responsável pela correspondência
Email: info@benthamscience.net

Abrar Ahmed

College of Pharmacy, University of Punjab

Email: info@benthamscience.net

Kiran Shahzadi

Department of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab

Email: info@benthamscience.net

Huma Riaz

Department of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab

Email: info@benthamscience.net

Bibliografia

  1. Valková, V.; Ďúranová, H.; Bilčíková, J.; Habán, M. Milk thistle (Silybum marianum): a valuable medicinal plant with several therapeutic purposes. J. Microbiol. Biotechnol. Food Sci., 2020, 9(4), 836-843. doi: 10.15414/jmbfs.2020.9.4.836-843
  2. Mayzlish-Gati, E.; Fridlender, M.; Nallathambi, R.; Selvaraj, G.; Nadarajan, S.; Koltai, H. Review on anti-cancer activity in wild plants of the Middle East. Curr. Med. Chem., 2018, 25(36), 4656-4670. doi: 10.2174/0929867324666170705113129 PMID: 28685674
  3. Javeria, M.; Hussain, K. Relationship between different agro-climatic conditions and silymarin production in wild milk thistle (Silybum marianum L. Gaert.) in Pakistan. Pak. J. Bot., 2022, 54(1), 179-185. doi: 10.30848/PJB2022-1(12)
  4. Sajad, M.A.; Khan, M.S.; Bahadur, S.; Naeem, A.; Ali, H.; Batool, F.; Shuaib, M.; Khan, M.A.S.; Batool, S. Evaluation of chromium phytoremediation potential of some plant species of Dir Lower, Khyber Pakhtunkhwa, Pakistan. Acta Ecol. Sin., 2020, 40(2), 158-165. doi: 10.1016/j.chnaes.2019.12.002
  5. Chambers, C.S. Holečková, V.; Petrásková, L.; Biedermann, D.; Valentová, K.; Buchta, M.; Křen, V. The silymarin composition and why does it matter??? Food Res. Int., 2017, 100(Pt. 3), 339-353. doi: 10.1016/j.foodres.2017.07.017 PMID: 28964357
  6. Abenavoli, L.; Izzo, A.A. Milić N.; Cicala, C.; Santini, A.; Capasso, R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother. Res., 2018, 32(11), 2202-2213. doi: 10.1002/ptr.6171 PMID: 30080294
  7. Andrew, R.; Izzo, A.A. Principles of pharmacological research of nutraceuticals. Br. J. Pharmacol., 2017, 174(11), 1177-1194. doi: 10.1111/bph.13779 PMID: 28500635
  8. Qavami, N.; Naghdi, B.H.; Labbafi, M.R.; Mehrafarin, A. A review on pharmacological, cultivation and biotechnology aspects of milk thistle (Silybum marianum (L.) Gaertn.). Faslnamah-i Giyahan-i Daruyi, 2013, 12(47), 19-37.
  9. Bijak, M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) Chemistry, bioavailability, and metabolism. Molecules, 2017, 22(11), 1942. doi: 10.3390/molecules22111942 PMID: 29125572
  10. Soleimani, V.; Delghandi, P.S.; Moallem, S.A.; Karimi, G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother. Res., 2019, 33(6), 1627-1638. doi: 10.1002/ptr.6361 PMID: 31069872
  11. Fanoudi, S.; Alavi, M.S.; Karimi, G.; Hosseinzadeh, H. Milk thistle (Silybum Marianum) as an antidote or a protective agent against natural or chemical toxicities: a review. Drug Chem. Toxicol., 2020, 43(3), 240-254. doi: 10.1080/01480545.2018.1485687 PMID: 30033764
  12. Zahra, N. A short review on ethnomedicinal uses and phytochemistry of Silybum marianum. Nat. Prod. Chem. Res., 2017, 5(7), 1000292. doi: 10.4172/2329-6836.1000292
  13. Won, D.H.; Kim, L.H.; Jang, B.; Yang, I.H.; Kwon, H.J.; Jin, B.; Oh, S.H.; Kang, J.H.; Hong, S.D.; Shin, J.A.; Cho, S.D. In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumour Biol., 2018, 40(5), 1010428318776170. doi: 10.1177/1010428318776170 PMID: 29764340
  14. Milić, N.; Milošević, N.; Suvajdžić, L.; Žarkov, M.; Abenavoli, L. New therapeutic potentials of milk thistle (Silybum marianum). Nat. Prod. Commun., 2013, 8(12), 1934578X1300801. doi: 10.1177/1934578X1300801236 PMID: 24555302
  15. Le, Q.U.; Lay, H.L.; Wu, M.C.; Joshi, R.K. Phytoconstituents and pharmacological activities of Silybum marianum (Milk Thistle): A critical review. Am. J. Essent. Oils Nat. Prod., 2018, 6(4), 41-47.
  16. Jahanafrooz, Z.; Motamed, N.; Rinner, B.; Mokhtarzadeh, A.; Baradaran, B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci., 2018, 213, 236-247. doi: 10.1016/j.lfs.2018.10.009 PMID: 30308184
  17. Csupor, D.; Csorba, A.; Hohmann, J. Recent advances in the analysis of flavonolignans of Silybum marianum. J. Pharm. Biomed. Anal., 2016, 130, 301-317. doi: 10.1016/j.jpba.2016.05.034 PMID: 27321822
  18. Sy-Cordero, A.; Graf, T.; Nakanishi, Y.; Wani, M.; Agarwal, R.; Kroll, D.; Oberlies, N. Large-scale isolation of flavonolignans from Silybum marianum extract affords new minor constituents and preliminary structure-activity relationships. Planta Med., 2010, 76(6), 644-647. doi: 10.1055/s-0029-1240624 PMID: 19941262
  19. Radusheva, P.; Pashev, A.; Uzunova, G.; Nikolova, K.; Gentscheva, G.; Perifanova, M.; Marudova, M. Physicochemical characteristics of seed oil of Sambucus ebulus, Coriandrum sativum L. and Silybum marianum L. Izv. Him., 2019, 51, 144-149.
  20. Qin, N.B.; Li, S.G.; Yang, X.Y.; Gong, C.; Zhang, X.Y.; Wang, J.; Li, D.H.; Guo, Y.Q.; Li, Z.L.; Hua, H.M. Bioactive terpenoids from Silybum marianum and their suppression on NO release in LPS-induced BV-2 cells and interaction with iNOS. Bioorg. Med. Chem. Lett., 2017, 27(10), 2161-2165. doi: 10.1016/j.bmcl.2017.03.058 PMID: 28377060
  21. AbouZid, S.F.; Chen, S.N.; McAlpine, J.B.; Friesen, J.B.; Pauli, G.F. Silybum marianum pericarp yields enhanced silymarin products. Fitoterapia, 2016, 112(112), 136-143. doi: 10.1016/j.fitote.2016.05.012 PMID: 27233988
  22. Fathi-Achachlouei, B.; Azadmard-Damirchi, S.; Zahedi, Y.; Shaddel, R. Microwave pretreatment as a promising strategy for increment of nutraceutical content and extraction yield of oil from milk thistle seed. Ind. Crops Prod., 2019, 128, 527-533. doi: 10.1016/j.indcrop.2018.11.034
  23. Mhamdi, B.; Abbassi, F.; Smaoui, A.; Abdelly, C.; Marzouk, B. Fatty acids, essential oil and phenolics composition of Silybum marianum seeds and their antioxidant activities. Pak. J. Pharm. Sci., 2016, 29(3), 953-959.
  24. Di Costanzo, A.; Angelico, R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules, 2019, 24(11), 2155. doi: 10.3390/molecules24112155 PMID: 31181687
  25. Cavaretta, M. Therapeutic review. Milk Thistle. J. Exot. Pet Med., 2015, 24(4), 470-472. doi: 10.1053/j.jepm.2015.09.001
  26. Abenavoli, L.; Capasso, R.; Milic, N.; Capasso, F. Milk thistle in liver diseases: Past, present, future. Phytother. Res., 2010, 24(10), 1423-1432. doi: 10.1002/ptr.3207 PMID: 20564545
  27. Vrba, J.; Papoušková, B.; Roubalová, L.; Zatloukalová, M.; Biedermann, D. Křen, V.; Valentová, K.; Ulrichová, J.; Vacek, J. Metabolism of flavonolignans in human hepatocytes. J. Pharm. Biomed. Anal., 2018, 152, 94-101. doi: 10.1016/j.jpba.2018.01.048 PMID: 29414024
  28. Fallah, M.; Davoodvandi, A.; Nikmanzar, S.; Aghili, S.; Mirazimi, S.M.A.; Aschner, M.; Rashidian, A.; Hamblin, M.R.; Chamanara, M.; Naghsh, N.; Mirzaei, H. Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer. Biomed. Pharmacother., 2021, 142, 112024. doi: 10.1016/j.biopha.2021.112024 PMID: 34399200
  29. Vilahur, G.; Casaní, L.; Peña, E.; Crespo, J.; Juan-Babot, O.; Ben-Aicha, S.; Mendieta, G.; Béjar, M.T.; Borrell, M.; Badimon, L. Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis. Int. J. Cardiol., 2018, 270, 28-35. doi: 10.1016/j.ijcard.2018.06.030 PMID: 29936043
  30. Porwal, O.; Mohammed Ameen, M.S.; Anwer, E.T.; Uthirapathy, S.; Ahamad, J.; Tahsin, A. Silybum marianum (Milk Thistle): Review on Its chemistry, morphology, ethno medical uses, phytochemistry and pharmacological activities. J. Drug Deliv. Ther., 2019, 9(5), 199-206. doi: 10.22270/jddt.v9i5.3666
  31. Zhang, Z.; Zhou, L.; Xie, N.; Nice, E.C.; Zhang, T.; Cui, Y.; Huang, C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct. Target. Ther., 2020, 5(1), 113. doi: 10.1038/s41392-020-00213-8 PMID: 32616710
  32. de Souza Santos, V.; Peters, B.; Côco, L.Z.; Alves, G.M.; de Assis, A.L.E.M.; Nogueira, B.V.; Meyrelles, S.S.; Porto, M.L.; Vasquez, E.C.; Campagnaro, B.P.; Pereira, T.M.C. Silymarin protects against radiocontrast-induced nephropathy in mice. Life Sci., 2019, 228, 305-315. doi: 10.1016/j.lfs.2019.04.061 PMID: 31047898
  33. Bahmani, M.; Shirzad, H.; Rafieian, S.; Rafieian-Kopaei, M. Silybum marianum: beyond hepatoprotection. J. Evid-based Complement. Altern. Med, 2015, 20(4), 292-301.
  34. Alzoubi, H.K.; Khabour, F.O.; Alkofahi, S.A.; Mhaidat, M.N.; Abu-Siniyeh, A.A. Anticancer and antimutagenic activity of Silybum marianum L. and Eucalyptus camaldulensis Dehnh. against skin cancer induced by DMBA: In vitro and in vivo models. Pak. J. Pharm. Sci., 2021, 34(3), 987-993. PMID: 34602423
  35. Iqbal, B.; Ali, J.; Ganguli, M.; Mishra, S.; Baboota, S. Silymarin-loaded nanostructured lipid carrier gel for the treatment of skin cancer. Nanomedicine, 2019, 14(9), 1077-1093. doi: 10.2217/nnm-2018-0235 PMID: 31050580
  36. Mastron, J.K.; Siveen, K.S.; Sethi, G.; Bishayee, A. Silymarin and hepatocellular carcinoma. Anticancer Drugs, 2015, 26(5), 475-486. doi: 10.1097/CAD.0000000000000211 PMID: 25603021
  37. Upadhyay, P.; Bhattacharjee, M.; Bhattacharya, S.; Ahir, M.; Adhikary, A.; Patra, P. Silymarin-loaded, lactobionic acid-conjugated porous PLGA nanoparticles induce apoptosis in liver cancer cells. ACS Appl. Bio Mater., 2020, 3(10), 7178-7192. doi: 10.1021/acsabm.0c00987 PMID: 35019376
  38. Zhao, X.; Deng, Y.; Zhang, Y.; Zu, Y.; Lian, B.; Wu, M.; Zu, C.; Wu, W. Silymarin nanoparticles through emulsion solvent evaporation method for oral delivery with high antioxidant activities, bioavailability, and absorption in the liver. RSC Advances, 2016, 6(95), 93137-93146. doi: 10.1039/C6RA12896C
  39. Bosch-Barrera, J.; Queralt, B.; Menendez, J.A. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treat. Rev., 2017, 58, 61-69. doi: 10.1016/j.ctrv.2017.06.003 PMID: 28686955
  40. Hajighasemlou, S.; Farajollahi, M.; Alebouyeh, M.; Rastegar, H.; Manzari, M.T.; Mirmoghtadaei, M.; Moayedi, B.; Ahmadzadeh, M.; Kazemi, M.; Parvizpour, F.; Gharibzadeh, S. Study of the effect of silymarin on viability of breast cancer cell lines. Adv. Breast Cancer Res., 2014, 3(3), 100-105. doi: 10.4236/abcr.2014.33015
  41. Gheybi, F.; Alavizadeh, S.H.; Rezayat, S.M.; Zendedel, E.; Jaafari, M. Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells. Nanomed. Res. J., 2019, 4(1), 29-34.
  42. Xia, Y.; Chang, T.; Wang, Y.; Liu, Y.; Li, W.; Li, M.; Fan, H.Y. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One, 2014, 9(3), e91770. doi: 10.1371/journal.pone.0091770 PMID: 24622501
  43. Lotfi, Z.; Salehi, E.; Morovati-sharifabad, M.; Sarkargar, F.; Pourghanbari, G. The effects of silibinin on SORT1 gene expression and A2780s ovarian cancer cell line viability. IJBSM, 2021, 6(3), 80-85. doi: 10.34172/ijbsm.2021.15
  44. Pashaei-Asl, F.; Pashaei-Asl, R.; Khodadadi, K.; Akbarzadeh, A.; Ebrahimie, E.; Pashaiasl, M. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif. Cells Nanomed. Biotechnol., 2018, 46(7), 1483-1487. doi: 10.1080/21691401.2017.1374281 PMID: 28884602
  45. Amawi, H.; Hussein, N.A.; Karthikeyan, C.; Manivannan, E.; Wisner, A.; Williams, F.E.; Samuel, T.; Trivedi, P.; Ashby, C.R., Jr; Tiwari, A.K. HM015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies. Front. Pharmacol., 2017, 8, 498. doi: 10.3389/fphar.2017.00498 PMID: 28824426
  46. Hosseinabadi, T.; Lorigooini, Z.; Tabarzad, M.; Salehi, B.; Rodrigues, C.F.; Martins, N.; Sharifi-Rad, J. Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer. Phytother. Res., 2019, 33(11), 2849-2861. doi: 10.1002/ptr.6470 PMID: 31407422
  47. Chipurupalli, S.; Kannan, E. Diverse actions of hypoxia-inducible factor 1 inhibitors in cancer. World J. Pharm. Res., 2018, 8(2), 669-684.
  48. You, Y.; Chen, L.; Wu, Y.; Wang, M.; Lu, H.; Zhou, X.; Liu, H.; Fu, Z.; He, Q.; Ou, J.; Fu, X.; Liu, Y.; Kwan, H.; Liang, D.; Zhao, X.; Dai, J. Silibinin promotes cell proliferation through facilitating G1/S transitions by activating drp1-mediated mitochondrial fission in cells. Cell Transplant., 2020, 29, 963689720950213. doi: 10.1177/0963689720950213 PMID: 32830544
  49. Wu, J.; Chen, C.; Zhao, K.N. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr. Cancer Drug Targets, 2013, 13(2), 143-156. doi: 10.2174/1568009611313020004 PMID: 23297827
  50. Imai-Sumida, M.; Chiyomaru, T.; Majid, S.; Saini, S.; Nip, H.; Dahiya, R.; Tanaka, Y.; Yamamura, S. Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget, 2017, 8(54), 92032-92042. doi: 10.18632/oncotarget.20734 PMID: 29190895
  51. Verma, K.K.; Goyal, S.; Gupta, G.D. Silymarin as herbal medicine- A review. Saudi J. Med. Pharm. Sci, 2018, 4, 36-48.
  52. Singh, T.; Prasad, R.; Katiyar, S.K. Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am. J. Cancer Res., 2016, 6(6), 1287-1301. PMID: 27429844
  53. Cufí, S.; Bonavia, R.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Corominas-Faja, B.; Cuyàs, E.; Martin-Castillo, B.; Barrajón-Catalán, E.; Visa, J.; Segura-Carretero, A.; Joven, J.; Bosch-Barrera, J.; Micol, V.; Menendez, J.A. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci. Rep., 2013, 3(1), 2459. doi: 10.1038/srep02459 PMID: 23963283
  54. Zhu, Z.; Sun, G. Silymarin mitigates lung impairments in a rat model of acute respiratory distress syndrome. Inflammopharmacology, 2018, 26(3), 747-754. doi: 10.1007/s10787-017-0407-3 PMID: 29098546
  55. Li, W.; Mu, D.; Song, L.; Zhang, J.; Liang, J.; Wang, C.; Liu, N.; Tian, F.; Li, X.; Zhang, W.; Wang, X. Molecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973. Cancer Biother. Radiopharm., 2011, 26(3), 317-324. doi: 10.1089/cbr.2010.0892 PMID: 21711112
  56. Zhang, Y.; Li, Q.; Ge, Y.; Chen, Y.; Chen, J.; Dong, Y.; Shi, W. Silibinin triggers apoptosis and cell-cycle arrest of SGC7901 cells. Phytother. Res., 2013, 27(3), 397-403. doi: 10.1002/ptr.4733 PMID: 22619007
  57. Bittencourt, M.L.F.; Rodrigues, R.P.; Kitagawa, R.R.; Gonçalves, R.C.R. The gastroprotective potential of silibinin against Helicobacter pylori infection and gastric tumor cells. Life Sci., 2020, 256, 117977. doi: 10.1016/j.lfs.2020.117977 PMID: 32603822
  58. Arafa Keshk, W.; Zahran, S.M.; Katary, M.A.; Abd-Elaziz Ali, D. Modulatory effect of silymarin on nuclear factor-erythroid-2-related factor 2 regulated redox status, nuclear factor-κB mediated inflammation and apoptosis in experimental gastric ulcer. Chem. Biol. Interact., 2017, 273, 266-272. doi: 10.1016/j.cbi.2017.06.022 PMID: 28648817
  59. Zhang, Y.; Ge, Y.; Ping, X.; Yu, M.; Lou, D.; Shi, W. Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines. Mol. Med. Rep., 2018, 18(2), 1835-1841. doi: 10.3892/mmr.2018.9129 PMID: 29901126
  60. Su, C.H.; Chen, L.J.; Liao, J.F.; Cheng, J.T. Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer. J. Med. Food, 2013, 16(9), 778-784. doi: 10.1089/jmf.2012.2534 PMID: 23909904
  61. Choi, E.S.; Oh, S.; Jang, B.; Yu, H.J.; Shin, J.A.; Cho, N.P.; Yang, I.H.; Won, D.H.; Kwon, H.J.; Hong, S.D.; Cho, S.D. Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. Cell. Oncol., 2017, 40(3), 235-246. doi: 10.1007/s13402-017-0318-8 PMID: 28401485
  62. Gohulkumar, M.; Gurushankar, K.; Rajendra Prasad, N.; Krishnakumar, N. Enhanced cytotoxicity and apoptosis-induced anticancer effect of silibinin-loaded nanoparticles in oral carcinoma (KB) cells. Mater. Sci. Eng. C, 2014, 41, 274-282. doi: 10.1016/j.msec.2014.04.056 PMID: 24907761
  63. Yang, C.Y.; Tsao, C.H.; Hsieh, C.C.; Lin, C.K.; Lin, C.S.; Li, Y.H.; Chang, W.C.; Cheng, J.C.; Lin, G.J.; Sytwu, H.K.; Wang, Y.L.; Chen, Y.W. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model. PLoS One, 2020, 15(7), e0236101. doi: 10.1371/journal.pone.0236101 PMID: 32678829
  64. Feng, W.; Cai, D.; Zhang, B.; Lou, G.; Zou, X. Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Biomed. Pharmacother., 2015, 74, 257-264. doi: 10.1016/j.biopha.2015.08.017 PMID: 26349994
  65. Shukla, S.K.; Dasgupta, A.; Mehla, K.; Gunda, V.; Vernucci, E.; Souchek, J.; Goode, G.; King, R.; Mishra, A.; Rai, I.; Nagarajan, S.; Chaika, N.V.; Yu, F.; Singh, P.K. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget, 2015, 6(38), 41146-41161. doi: 10.18632/oncotarget.5843 PMID: 26510913
  66. Anestopoulos, I.; Sfakianos, A.; Franco, R.; Chlichlia, K.; Panayiotidis, M.; Kroll, D.; Pappa, A. A novel role of silibinin as a putative epigenetic modulator in human prostate carcinoma. Molecules, 2016, 22(1), 62. doi: 10.3390/molecules22010062 PMID: 28042859
  67. Krishna, P.M. Silymarin microspheres and its antiproliferative action on human prostate adenomatous cancer du145 cells. World J. Pharm. Pharm. Sci., 2014, 3(5), 1447-1457.
  68. Gioti, K.; Papachristodoulou, A.; Benaki, D.; Havaki, S.; Beloukas, A.; Vontzalidou, A.; Aligiannis, N.; Skaltsounis, A.L.; Mikros, E.; Tenta, R. Silymarin enriched extract (Silybum marianum) additive effect on doxorubicin-mediated cytotoxicity in PC-3 prostate cancer cells. Planta Med., 2019, 85(11/12), 997-1007. doi: 10.1055/a-0954-6704 PMID: 31288278
  69. Faezizadeh, Z.; Mesbah-Namin, S.; Allameh, A. The effect of silymarin on telomerase activity in the human leukemia cell line K562. Planta Med., 2012, 78(9), 899-902. doi: 10.1055/s-0031-1298464 PMID: 22532022
  70. Elyasi, S.; Hosseini, S.; Niazi, M.M.R.; Aledavood, S.A.; Karimi, G. Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double‐blinded, placebo‐controlled clinical trial. Phytother. Res., 2016, 30(11), 1879-1885. doi: 10.1002/ptr.5704 PMID: 27555604
  71. Bai, Z.L.; Tay, V.; Guo, S.Z.; Ren, J.; Shu, M.G. Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP. BioMed Res. Int., 2018, 2018, 6165192. doi: 10.1155/2018/6165192
  72. Delmas, D.; Xiao, J.; Vejux, A.; Aires, V. Silymarin and cancer: A dual strategy in both in chemoprevention and chemosensitivity. Molecules, 2020, 25(9), 2009. doi: 10.3390/molecules25092009 PMID: 32344919
  73. Baradaran, A.; Samadi, F.; Ramezanpour, S.S.; Yousefdoust, S. Hepatoprotective effects of silymarin on CCl4-induced hepatic damage in broiler chickens model. Toxicol. Rep., 2019, 6, 788-794. doi: 10.1016/j.toxrep.2019.07.011 PMID: 31440455
  74. Mukhtar, S.; Xiaoxiong, Z.; Qamer, S.; Saad, M.; Mubarik, M.S.; Mahmoud, A.H.; Mohammed, O.B. Hepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats. Saudi J. Biol. Sci., 2021, 28(1), 717-723. doi: 10.1016/j.sjbs.2020.10.063 PMID: 33424359
  75. Masarone, M.; Rosato, V.; Dallio, M.; Abenavoli, L.; Federico, A.; Loguercio, C.; Persico, M. Epidemiology and natural history of alcoholic liver disease. Rev. Recent Clin. Trials, 2016, 11(3), 167-174. doi: 10.2174/1574887111666160810101202 PMID: 27515957
  76. Abenavoli, L.; Masarone, M.; Federico, A.; Rosato, V.; Dallio, M.; Loguercio, C.; Persico, M. Alcoholic hepatitis: pathogenesis, diagnosis and treatment. Rev. Recent Clin. Trials, 2016, 11(3), 159-166. doi: 10.2174/1574887111666160724183409 PMID: 27457347
  77. Nanda, V.; Gupta, V.; Sharma, S.N.; Pasricha, A.; Karmakar, A.K.; Patel, A.; Bhatt, V.M.; Kantroo, B.L.; Kumar, B.; Paul, N.K.; Attam, R. Effect of Liverubin™ on hepatic biochemical profile in patients of alcoholic liver disease: a retrospective study. Minerva Med., 2014, 105, 1-8. PMID: 26076375
  78. Tighe, S.P.; Akhtar, D.; Iqbal, U.; Ahmed, A. Chronic liver disease and silymarin: A biochemical and clinical review. J. Clin. Transl. Hepatol., 2020, 8(4), 1-5. doi: 10.14218/JCTH.2020.00012 PMID: 33447529
  79. Milosević N.; Milanović M.; Abenavoli, L.; Milić N. Phytotherapy and NAFLD-from goals and challenges to clinical practice. Rev. Recent Clin. Trials, 2015, 9(3), 195-203. doi: 10.2174/1574887109666141216110337 PMID: 25514914
  80. Solhi, H.; Ghahremani, R.; Kazemifar, A.M.; Hoseini Yazdi, Z. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J. Intern. Med., 2014, 5(1), 9-12. PMID: 24490006
  81. Wah Kheong, C.; Nik Mustapha, N.R.; Mahadeva, S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol., 2017, 15(12), 1940-1949.e8. doi: 10.1016/j.cgh.2017.04.016 PMID: 28419855
  82. Curcio, A.; Romano, A.; Cuozzo, S.; Di Nicola, A.; Grassi, O.; Schiaroli, D.; Nocera, G.F.; Pironti, M. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina, 2020, 56(10), 544. doi: 10.3390/medicina56100544 PMID: 33080906
  83. Esmaeil, N.; Anaraki, S.B.; Gharagozloo, M.; Moayedi, B. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int. Immunopharmacol., 2017, 50, 194-201. doi: 10.1016/j.intimp.2017.06.030 PMID: 28672215
  84. Shahidi, M.; Vaziri, F.; Haerian, A.; Farzanegan, A.; Jafari, S.; Sharifi, R.; Shirazi, F.S. Proliferative and anti-inflammatory effects of resveratrol and silymarin on human gingival fibroblasts: A view to the future. J. Dent., 2017, 14(4), 203-211. PMID: 29285030
  85. Hussain, S.A.; Jassim, N.A.; Numan, I.T.; Al-Khalifa, I.I.; Abdullah, T.A. Anti-inflammatory activity of silymarin in patients with knee osteoarthritis. A comparative study with piroxicam and meloxicam. Saudi Med. J., 2009, 30(1), 98-103. PMID: 19139781
  86. Ahmed Aziz, T.; Hasan Marouf, B.; Aorahman Ahmed, Z.; Abdulrahman Hussain, S. Anti-inflammatory activity of silibinin in animal models of chronic inflammation. Am. J. Pharmacol. Sci., 2014, 2(1), 7-11. doi: 10.12691/ajps-2-1-2
  87. Azadpour, M.; Farajollahi, M.M.; Varzi, A.M.; Hashemzadeh, P.; Mahmoudvand, H.; Barati, M. Extraction, chemical composition, antioxidant property, and in vitro anticancer activity of silymarin from Silybum marianum on Kb and A549 cell lines. Curr. Drug Discov. Technol., 2021, 18(4), 511-517. doi: 10.2174/1570163817666200827111127 PMID: 32860361
  88. Al Atraqchi, N.H.; Shaikh Hamed, W.M.A.A. Preliminary phytochemical screening and in vitro evaluation of antioxidant activity of Iraqi species of Silybum marianum seeds. Int. Res. J. Pharm., 2014, 5(5), 378-383. doi: 10.7897/2230-8407.050579
  89. Serçe, A. Toptancı B.Ç.; Tanrıkut, S.E.; Altaş S.; Kızıl, G.; Kızıl, S.; Kızıl, M. Assessment of the antioxidant activity of Silybum marianum seed extract and its protective effect against DNA oxidation, protein damage and lipid peroxidation. Food Technol. Biotechnol., 2016, 54(4), 455-461. doi: 10.17113/ftb.54.04.16.4323 PMID: 28115903
  90. Colturato, C.P.; Constantin, R.P.; Maeda, A.S., Jr; Constantin, R.P.; Yamamoto, N.S.; Bracht, A.; Ishii-Iwamoto, E.L.; Constantin, J. Metabolic effects of silibinin in the rat liver. Chem. Biol. Interact., 2012, 195(2), 119-132. doi: 10.1016/j.cbi.2011.11.006 PMID: 22137898
  91. Abenavoli, L.; Milic, N.; Capasso, F. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine, 2012, 42(3), 754-755. doi: 10.1007/s12020-012-9677-0 PMID: 22527892
  92. Di Pierro, F.; Putignano, P.; Montesi, L.; Moscatiello, S.; Marchesini Reggiani, G.; Villanova, N. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin. Pharmacol., 2013, 5, 167-174. doi: 10.2147/CPAA.S54308 PMID: 24277991
  93. Ebrahimpour Koujan, S.; Gargari, B.P.; Mobasseri, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine, 2015, 22(2), 290-296. doi: 10.1016/j.phymed.2014.12.010 PMID: 25765835
  94. Mohammadi Arvanag, F.; Bayrami, A.; Habibi-Yangjeh, A.; Rahim Pouran, S. A comprehensive study on antidiabetic and antibacterial activities of ZnO nanoparticles biosynthesized using Silybum marianum L. seed extract. Mater. Sci. Eng. C, 2019, 97, 397-405. doi: 10.1016/j.msec.2018.12.058 PMID: 30678925
  95. Abed, I.J.; Al-Moula, R.; Abdulhasan, G.A. Antibacterial effect of flavonoids extracted from seeds of Silybum marianum against common pathogenic bacteria. World J. Exp. Biosci., 2015, 3(1), 36-39.
  96. de Oliveira, D.R.; Tintino, S.R.; Braga, M.F.; Boligon, A.A.; Athayde, M.L.; Coutinho, H.D.; de Menezes, I.R.; Fachinetto, R. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. BioMed Res. Int., 2015, 2015, 292797. PMID: 25866771
  97. Bajwa, A.; Tariq, S.; Yuchi, A.; Hafeez, R.; Arshad, A.; Zaman, M.; Aqeel, T.; Mushtaq, M.N. Evaluation of anti-bacterial activity of Silybum marianum against pathogenic and resistant bacteria. Eur. J. Med. Chem., 2016, 13(4), 1-7.
  98. Salamone, F.; Galvano, F.; Marino, A.; Paternostro, C.; Tibullo, D.; Bucchieri, F.; Mangiameli, A.; Parola, M.; Bugianesi, E.; Li Volti, G. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig. Liver Dis., 2012, 44(4), 334-342. doi: 10.1016/j.dld.2011.11.010 PMID: 22197629
  99. Anestopoulos, I.; Kavo, A.; Tentes, I.; Kortsaris, A.; Panayiotidis, M.; Lazou, A.; Pappa, A. Silibinin protects H9c2 cardiac cells from oxidative stress and inhibits phenylephrine-induced hypertrophy: Potential mechanisms. J. Nutr. Biochem., 2013, 24(3), 586-594. doi: 10.1016/j.jnutbio.2012.02.009 PMID: 22818713
  100. Shahbazi, F.; Dashti-Khavidaki, S.; Khalili, H.; Lessan-Pezeshki, M. Potential renoprotective effects of silymarin against nephrotoxic drugs: A review of literature. J. Pharm. Pharm. Sci., 2012, 15(1), 112-123. doi: 10.18433/J3F88S PMID: 22365093
  101. Ullah, H.; Khan, H. Anti-Parkinson potential of silymarin: Mechanistic insight and therapeutic standing. Front. Pharmacol., 2018, 9, 422. doi: 10.3389/fphar.2018.00422 PMID: 29755356
  102. Wang, C.; Wang, Z.; Zhang, X.; Zhang, X.; Dong, L.; Xing, Y.; Li, Y.; Liu, Z.; Chen, L.; Qiao, H.; Wang, L.; Zhu, C. Protection by silibinin against experimental ischemic stroke: Up-regulated pAkt, pmTOR, HIF-1α and Bcl-2, down-regulated Bax, NF-κB expression. Neurosci. Lett., 2012, 529(1), 45-50. doi: 10.1016/j.neulet.2012.08.078 PMID: 22999929
  103. Sayyah, M.; Boostani, H.; Pakseresht, S.; Malayeri, A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(2), 362-365. doi: 10.1016/j.pnpbp.2009.12.016 PMID: 20035818
  104. Behl, A.; Swami, G.; Sircar, S.S.; Bhatia, M.S.; Banerjee, B.D. Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder. Neuropsychobiology, 2010, 61(4), 210-214. doi: 10.1159/000306591 PMID: 20389131
  105. Nazir, N.; Karim, N.; Abdel-Halim, H.; Khan, I.; Wadood, S.F.; Nisar, M. Phytochemical analysis, molecular docking and antiamnesic effects of methanolic extract of Silybum marianum (L.) Gaertn seeds in scopolamine induced memory impairment in mice. J. Ethnopharmacol., 2018, 210, 198-208. doi: 10.1016/j.jep.2017.08.026 PMID: 28842342
  106. Peila, C.; Coscia, A.; Tonetto, P.; Spada, E.; Milani, S.; Moro, G.; Fontana, C.; Vagliano, L.; Tortone, C.; Di Bella, E.; Bertino, E.; Bertino, E. Evaluation of the galactogogue effect of silymarin on mothers of preterm newborns (<32 weeks). Pediatr. Med. Chir., 2015, 37(3), 105. doi: 10.4081/pmc.2015.105 PMID: 26714778
  107. Olagaray, K.E.; Bradford, B.J. Plant flavonoids to improve productivity of ruminants – A review. Anim. Feed Sci. Technol., 2019, 251, 21-36. doi: 10.1016/j.anifeedsci.2019.02.004
  108. Serviddio, G.; Bellanti, F.; Stanca, E.; Lunetti, P.; Blonda, M.; Tamborra, R.; Siculella, L.; Vendemiale, G.; Capobianco, L.; Giudetti, A.M. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic. Biol. Med., 2014, 73, 117-126. doi: 10.1016/j.freeradbiomed.2014.05.002 PMID: 24819445
  109. Trakulsrichai, S.; Sriapha, C.; Tongpoo, A.; Udomsubpayakul, U.; Wongvisavakorn, S.; Srisuma, S.; Wananukul, W. Clinical characteristics and outcome of toxicity from Amanita mushroom poisoning. Int. J. Gen. Med., 2017, 10, 395-400. doi: 10.2147/IJGM.S141111 PMID: 29138589
  110. Santi, L.; Maggioli, C.; Mastroroberto, M.; Tufoni, M.; Napoli, L.; Caraceni, P. Acute liver failure caused by Amanita phalloides poisoning. Int. J. Hepatol., 2012, 2012, 487480.
  111. Mengs, U.; Torsten Pohl, R.; Mitchell, T. Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr. Pharm. Biotechnol., 2012, 13(10), 1964-1970. doi: 10.2174/138920112802273353 PMID: 22352731

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2023